Bempikibart

Monoclonal antibody

Also known as ADX-914

Earlyevidence

Evidence outlook

Mid-stage readout reported

A Phase 2 readout has been reported. The trial rows below carry the recorded result.

Latest reported trial: SIGNAL-AD (NCT05509023) · Phase 2 · missed primary endpoint · grade pending

Also in development:Alopecia Areata · Phase 2

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 2 (2)
Alopecia Areata
Atopic Dermatitis
Phase 1 (1)
Other / comorbidity
NCT04485481 · Q32 Bio Inc.
2020-09-08 – 2022-01-12 · Safety Issues
What this study did

Competitive landscape

This drug's own stage for Alopecia Areata: Phase 2. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Bempikibart: this drugPhase 2Monoclonal antibodyIL-7 receptor alphaPartial signal
NCT06018428: Part A primary, mean relative percent change in SALT score at week 24 vs placebo: the planned primary analysis was not performed after one site was excluded for protocol violations, so no primary-analysis result exists. Post-hoc per-protocol analysis (SALT 50-100): bempikibart (n=23) 16% mean reduction vs placebo (n=4) 2% reduction; Wilcoxon rank sum p=0.045. Part B is single-arm and has no comparison.
Baricitinib (Olumiant)ApprovedSmall moleculeJAK, JAK1/2not yet gradedNo reviewed efficacy summary in this indication
Jaktinib (Zepuping)Phase 3Small moleculeJAK1/2/3Partial signal
NCT05051761: Primary endpoint, SALT score <=20 at week 24: both jaktinib doses superior to placebo (p<0.0001) (2024-06-13).
Upadacitinib (Rinvoq)Phase 3Small moleculeJAK, JAK1not yet gradedNo reviewed efficacy summary in this indication
RezpegaldesleukinPhase 2Protein / enzyme therapeuticIL-2 mutein (Treg-selective)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

No upcoming readouts on record for this asset.

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

13 July 2026Topline resultSIGNAL-AA Part B 36-week topline results
US · Q32 Bio · Source ↗